3. Outcome summary: side effects and satisfaction.
Study | N | Experimental intervention | Delivery | Side effects or adverse events | Satisfaction or acceptability |
NSAID | |||||
Karabayirli 2012 | 103 | Naproxen 550 mg | Tablet | 0 | Unsatisfied: naproxen < placebo |
Hubacher 2006 | 2019 | Ibuprofen 400 mg | Tablet, oral | _ | _ |
Jensen 1998 | 55 | Ibuprofen 600 mg | Tablet, oral | _ | _ |
Bednarek 2015 | 202 | Ibuprofen 800 mg | Tablet, oral | _ | _ |
Chor 2012 | 87 | Ibuprofen 800 mg | Tablet, oral | 0 | _ |
Massey 1974 | 58 | Naproxen 300 mg (x 4 doses) + paracervical block (1% lidocaine 8 mL) | Tablet, oral | NAa | _ |
Ngo 2014 | 67 | Ketorolac 30 mg | Intramuscular injection | NA | NA |
Lidocaine | |||||
Maguire 2012 | 200 | 2% gel (1 mL) | Swab | NA | NA |
Mohammad‐Alizadeh‐C 2010 | 96 | 2% gel | Swab | _ | _ |
Allen 2013 | 150 | 2% gel (6 mL) | 2 sites, 3 mL each | NSc | NS |
Nelson 2013 | 40 | 2% (1.2 mL) | Infused, 3 sites | _ | _ |
McNicholas 2012 | 200 | 2% gel (2.5 to 4 mL) | 0.5 to 1 mL Topical; 2 to 3 mL inserted | NA | _ |
Rapkin 2014 | 64 | 2% gel (5 mL) | Self‐inserted vaginally | _ | NA |
Tornblom‐Paulander 2015 | 218 | 4% gel (8.5 mL) | Topical, 3 sites | NS | _ |
Aksoy 2015 | 200 | 10% spray (40 mg) | Topical, 2 sites; 4 puffs total | NA | _ |
Ahmadi Doulabi 2013 | 92 | EMLA cream 5% (lidocaine + prilocaine) (5 g) | Swab | _ | _ |
Mody 2012 | 50 | 1% paracervical block (10 mL) | 2 sites, 5 mL each | NS | _ |
Cırık 2013b | 95 | 1% paracervical block (10 mL) | 2 sites, 5 mL each | NS | _ |
Castro 2014 | 100 | 2% intracervical block (1.8 mL) | 4 sites | _ | NS |
Misoprostol | |||||
Sääv 2007 | 80 | 400 μg + diclofenac | Sublingual | Shivering: misoprostol > placebo; Other: NS | NS |
Ibrahim 2013 | 274 | 400 µg + diclofenac | sublingual | Headache or abdominal pain: misoprostol > placebo; Other: NS | Choose again or recommend to friend: misoprostol < control |
Heikinheimo 2010 | 89 | 400 µg | Sublingual | NS | _ |
Edelman 2011 | 40 | 400 µg | Buccal | NS | _ |
Lathrop 2013 | 73 | 400 µg | Buccal | _ | NS |
Espey 2014 | 83 | 400 µg | Buccal | NS | NS |
Lotke 2013 | 61 | 400 μg | Vaginal or buccal | NS | NS |
Swenson 2012 | 108 | 400 μg | Vaginal or buccal | NA | NS |
Dijkhuizen 2011 | 270 | 400 μg | Vaginal | NS | _ |
Scavuzzi 2013 | 190 | 400 μg | Vaginal | NS | Misoprostol > placebo |
Other | |||||
Bednarek 2013 | 24 | Nitroprusside gel 1% | 1 mL | NS | Satisfaction with pain control: NS; Satisfaction with procedure: nitroprusside < placebo |
Micks 2014 | 24 | Nitroglycerin ointment 0.5 mg | 1 mL | NS | Satisfaction with pain control or procedure: NS |
Karabayirli 2012 | 103 | Tramadol 50 mg | Tablet | None | NS |
Shahnazi 2012 | 106 | Lavender 10 drops in diluted milk | 3 drops on cotton, inhaled | None | _ |
Cameron 2013 | 200 | Delayed bladder emptying (after IUC insertion) | Oral (water 1 L) | _ | _ |
aNA = not available (assessed but not reported, or provided insufficient data) bExcluded from sensitivity analysis due to low quality evidence cNS = no significant difference between study arms